Get the Daily Brief
Latest Biotech News
Obesity breakthrough: Lilly’s retatrutide posts Phase 3 “high-water mark”
Eli Lilly said its triple-agonist retatrutide delivered weight loss results that set a new benchmark in Phase 3 for people with obesity and type 2 diabetes, supported by multi-measure improvements...
AstraZeneca bets on Summit’s PD-1/VEGF bispecific for ADC combinations
AstraZeneca announced a $2 billion equity investment in Summit Therapeutics centered on ivonescimab, a PD-1/VEGF bispecific, as the companies move to build combination trials pairing the agent...
Regulatory rollback: Merck and Daiichi withdraw BLA for ifinatamab deruxtecan in SCLC
Merck and Daiichi Sankyo withdrew their FDA biologics license application for ifinatamab deruxtecan (i-dxd), removing the path they sought for accelerated approval in extensive-stage small cell...
KRAS G12D molecular glue licensing: Merck seals SciBrunch deal
Merck completed an exclusive global licensing and collaboration deal with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor described as a precision cancer candidate...
Obesity pipeline expansion via China-to-Global deal: Novo licenses Hengrui’s weekly oral GLP-1/GIP agonist
Novo Nordisk agreed to license ex-China rights to Hengrui Pharmaceuticals’ once-weekly, oral dual GLP-1R/GIPR agonist HRS-1596, adding another candidate in its effort to broaden metabolic disease...
Phase 3 win in wet AMD: Kodiak advances longer-interval tarcocimab tedromer and tabirafusp tedromer
Kodiak Sciences reported Phase 3 positive results in wet age-related macular degeneration, with its Zenkuda (tarcocimab tedromer) meeting non-inferiority versus aflibercept and with a dosing...
Beam vs. YolTech/Serapha: alleged base-editing trade secret theft fuels new legal fight
Beam Therapeutics filed suit accusing YolTech Therapeutics and Serapha Bio of stealing base-editing intellectual property, alleging that a former Beam scientist co-founded YolTech while still...
UniQure Huntington gene therapy durability concern after four-year readout
UniQure’s Huntington’s disease gene therapy AMT-130 came under fresh scrutiny after additional four-year follow-up data suggested the magnitude of benefit may have waned relative to earlier...
Apheris and Ginkgo form Antibody Developability Consortium to de-risk manufacturing
Ginkgo Datapoints and Apheris launched the Antibody Developability Consortium, aiming to build a standardized dataset to predict antibody manufacturability and developability risks earlier in the...
AI + proteomics accelerate molecular glue discovery targeting VAV1
A Baylor College of Medicine-led team combined high-throughput proteomics and AI-based structure prediction to discover and optimize molecular glue candidates designed to degrade VAV1, an immune...
Obesity drug pipelines surge with late-stage results and weekly dosing bets
Eli Lilly pushed next-generation weight-loss into sharper focus as phase 3 data for retatrutide (TRIUMPH-2) showed dose-dependent, large-scale weight loss in people with obesity and type 2...
Big Pharma doubles down on PD-1/VEGF bispecific combinations
AstraZeneca escalated its oncology strategy by investing $2 billion in Summit Therapeutics, taking equity in exchange for collaboration plans to pair Summit’s PD-1/VEGF bispecific ivonescimab with...
Merck ramps precision oncology licensing for KRAS G12D molecular glue
Merck secured global rights to a preclinical KRAS G12D (ON) inhibitor-molecular glue program from China’s SciBrunch Therapeutics in a licensing and collaboration deal valued at up to $2.13...
Regulatory setbacks thin the FDA pipeline calendar for antibody-drug conjugates
Merck and Daiichi Sankyo withdrew their BLA for ifinatamab deruxtecan (i-dxd), a B7-H3-directed ADC for extensive-stage small-cell lung cancer, ahead of its October PDUFA date. The change removes...
UniQure’s Huntington gene therapy durability comes under renewed scrutiny
UniQure’s Huntington’s disease gene therapy AMT-130 is facing renewed durability questions after additional four-year follow-up data showed a smaller magnitude of benefit versus earlier analyses....
SciBrunch and VAV1 molecular glue science points toward faster targeted protein degradation
Researchers at Baylor College of Medicine reported an AI- and proteomics-driven approach to discovering molecular glues that degrade VAV1, a signaling protein implicated in blood cancers and...
AstraZeneca’s ADC-plus-bispecific strategy expands through Summit equity and clinical planning
AstraZeneca’s $2 billion investment in Summit is designed not only to fund development but to operationalize combination testing for ivonescimab alongside AstraZeneca’s ADC pipeline. Clinical...
Merck and SciBrunch intellectual-property and deal momentum intersects with precision oncology licensing
Merck’s licensing deal with SciBrunch further cements the company’s focus on building next waves of precision oncology programs through external innovation sourcing. The deal covers development,...
Link Cell names leadership for CAR T start-up focused on scalable autoimmune cell therapy
CAR T start-up Link Cell appointed a new leadership team as it builds out its allogeneic approach to autoimmune therapeutics. The company named Jie D’Elia as CEO, with Friedrich Graf Finckenstein...
New trial-ready and investor-backed platforms in immune and metabolic disease
A pair of early-stage developments highlighted how companies are converting platform science into near-term clinical execution. Regcell raised $66 million, including Japanese government support,...